[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-effusion-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":34,"states":39},"Primary Effusion Lymphoma",4,[7,15,22,28],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT05907759","Daratumumab for Relapsed\u002FRefractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease",[11],"Phase 2","RECRUITING","2026-08-26T02:18:43.501109Z","2026-05-05T02:43:26.949844Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT04902443","Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIV",[19],"Phase 1","2026-08-26T02:17:27.435233Z","2026-06-18T12:24:02.872345Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":26,"content_modified":27},"NCT04968288","Natural History of KSHV-Associated Multicentric Castleman s Disease",[],"2026-08-26T02:19:07.104270Z","2026-05-13T02:55:06.275783Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":32,"content_modified":33},"NCT00006518","Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer",[],"2026-08-26T02:17:21.315591Z","2026-05-13T02:55:06.028653Z",[35],{"biomarker":36,"count":37,"slug":38},"KSHV",3,"kshv",[40],{"state":41,"count":5,"slug":42},"Maryland","maryland"]